**In the Specification:**

Please replace the paragraph beginning at page 10, line 14, with the following amended paragraph:

The tripeptide sequence of TRI 50b has three chiral centres. The Phe residue is considered to be of (R)-configuration and the Pro residue of natural (S)-configuration, at least in compounds with commercially useful inhibitor activity; the Mpg residue is believed to be of (R)-configuration in isomers with commercially useful inhibitor activity. Thus, the active, or most active, TRI 50b stereoisomer is considered to be of R,S,R configuration and may be represented as:




(RSR)-TRI 50b: Cbz-(R)-Phe-(S)-Pro-(R)-boroMpg Pinacol




(R,S,R)-TRI 50b: Cbz-(R)-Phe-(S)-Pro-(R)-boroMpg-Pinacol

Please replace the paragraph beginning at page 26, line 1, with the following amended paragraph:

The $aa^1$ moiety of the salt is preferably of (R)-configuration. The $aa^2$ moiety is preferably of (S)-configuration. Particularly preferred salts have $aa^1$ of (R)-configuration and $aa^2$ of (S)-configuration. The chiral centre –NH-CH($R^1$)-B- is preferably of (R)-configuration. It is considered that commercial formulations will have the chiral centres in (R,S,R) arrangement, as for example in the case of salts of Cbz-Phe-Pro-BoroMpg-OH:




Cbz-(R)-Phe-(S)-Pro-(R)-boroMpg-OH




Cbz-(R)-Phe-(S)-Pro-(R)-boroMpg-OH

Please replace the paragraph beginning at page 52, line 1, with the following amended paragraph:




LDA = lithium diisopropylamide

LiHMDS = lithium hexamethyldisilazane, also known as lithium bis(trimethylsilyl)amide




LDA = lithium diisopropylamide

LiHMDS = lithium hexamethyldisilazane, also known as lithium bis(trimethylsilyl)amide